Ultime notizie per Hancock Whitney (NASDAQ:HWC) Azioni

Hancock Whitney

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations and individuals and provides its customers access to investment advisory and brokerage products.

Hancock Whitney Corporation - Common Stock

Hancock Whitney Corp

Hancock Whitney Corporation - 6.25% Subordinated Notes due 2060

STOCK RISES 1.7%
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="791" height="810" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/14205328/Screen-Shot-2024-10-14-at-4.51.49-PM.png" alt="" class="wp-image-2344" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/14205328/Screen-Shot-2024-10-14-at-4.51.49-PM.png 791w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/14205328/Screen-Shot-2024-10-14-at-4.51.49-PM-293x300.png 293w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/14205328/Screen-Shot-2024-10-14-at-4.51.49-PM-768x786.png 768w" sizes="(max-width: 791px) 100vw, 791px" /></figure>
Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:19 AM on October 14th, a significant trading signal occurred for Caterpillar, Inc. as it demonstrated a Power Inflow at a price of $388.65. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Caterpillar&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Caterpillar&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and studies both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted by active traders as a bullish signal.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for CAT, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $388.65. The returns on the High price ($396.28) and Close price ($394.14) after the Power Inflow are respectively 1.7% and 1.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past Performance is Not Indicative of Future Results

Signals

Trading Ideas

General

Tradepulse Power Inflow Alert: Caterpillar Inc. Receives Alert And Rises Over 7 Points

A political committee opposing Florida&#8217;s cannabis legalization measure has received a $500,000 donation from an organization reportedly linked to Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO <a href="https://www.benzinga.com/topic/elon-musk">Elon Musk</a>'s prior support of Gov.<a href="https://www.benzinga.com/23/05/32545295/ron-desantis-or-tim-scott-elon-musk-says-he-wants-this-person-to-be-next-president"> Ron DeSantis's primary presidential bid</a>. The financial boost comes as the campaign pushing for cannabis legalization crosses $100 million in contributions.
Florida's cannabis legalization initiative, known as&nbsp;Amendment 3, is set to go before Florida voters in&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noreferrer noopener">the upcoming November elections</a>.
The Florida branch of the American Civil Liberties Union (ACLU) posted a familiar video while commenting on Musk&#8217;s anti-cannabis move, which is followed by a breakdown of the campaign finance database provided by Florida investigative reporter Jason Garcia, who covers corporate influence in Florida.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">You mean this Elon Musk is against legal cannabis in Florida? Vote yes on Amendment 3 and let's end the drug war in Florida.<a href="https://t.co/8qLhPqTlWA">pic.twitter.com/8qLhPqTlWA</a> <a href="https://t.co/JAMvBnTsyM">https://t.co/JAMvBnTsyM</a>
&mdash; ACLU of Florida (@ACLUFL) <a href="https://twitter.com/ACLUFL/status/1844924362622930994?ref_src=twsrc%5Etfw">October 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Read Also: <a href="EXCLUSIVE: Elon Musk's X Is 'Safe Space' To Say Weed: 'The Only Social Platform Where You Can Talk About Cannabis Openly'">EXCLUSIVE: Elon Musk&#8217;s X Is &#8216;Safe Space&#8217; To Say Weed: &#8216;The Only Social Platform Where You Can Talk About Cannabis Openly&#8217;</a></figcaption></figure>
<h1 class="wp-block-heading"> Musk Money To &#8216;Keep Florida Clean&#8217;?</h1>
The so-called Faithful &amp; Strong Policies, Inc., which is headed by Florida attorney Scott Wagner, made the contribution to <a href="https://www.benzinga.com/markets/cannabis/24/08/40486924/ken-griffins-12m-donation-and-desantiss-anti-cannabis-pacs-face-off-against-pro-legalization-gro">Keep Florida Clean</a>, a group dedicated to defeating Amendment 3, according to <a href="https://dos.elections.myflorida.com/committees/ComDetail.asp?account=88582">campaign filings</a> (seen above). Keep Florida Clean and the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/06/39565658/desantis-anti-cannabis-florida-freedom-fund-raises-barely-a-fraction-of-legalization-committees-" target="_blank" rel="noreferrer noopener">Florida Freedom Fund</a> are both chaired by James Uthmeier, DeSantis&#8217; chief of staff and former campaign manager when the governor ran for president.
The half-million dollar injection into the anti-legalization campaign comes with just three weeks to go before the election and shortly after a new poll showing majority support for the cannabis measure, though not quite enough to meet the 60% requirement to pass the constitutional amendment. The latest <a href="https://floridapolitics.com/archives/701476-poll-abortion-recreational-pot-measures-have-majority-support-but-just-1-has-enough-backing-to-pass/">NBC 6 poll</a>, conducted from October 1-4 showed 58% of voters support the measure, falling just two points short of the threshold.
The said, the $500,000 pales in comparison to the over $100 million raised by <a href="https://drupal-cloudfront.benzinga.com/topic/smart-safe-florida">Smart &amp; Safe Florida</a>, the committee that helped put the cannabis legalization amendment on the ballot. As of late August, the legalization amendment had pulled in at least $91 million <a href="https://news.ballotpedia.org/2024/09/18/florida-amendment-3-exceeds-previous-records-for-marijuana-legalization-campaign-contributions/">according to Ballotpedia</a>, the vast majority of which was provided by the state's largest medical marijuana operator Trulieve Cannabis Corp&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>).
While Musk's connection to Faithful &amp; Strong Policies at the moment is uncertain, The Wall Street Journal <a href="https://www.wsj.com/politics/policy/elon-musk-political-donations-stephen-miller-desantis-39464294">reported</a> that he previously contributed $10 million to the organization, with about half of that supporting DeSantis's presidential campaign. Marijuana Moment first <a href="https://www.marijuanamoment.net/group-thats-been-backed-by-elon-musk-donates-500000-to-anti-marijuana-legalization-effort-in-florida/">reported</a> this story.
Meanwhile, DeSantis has been actively rallying opposition to the initiative as his administration has faced criticism over a <a href="https://www.benzinga.com/markets/cannabis/24/10/41207561/desantis-state-of-florida-under-fire-for-taxpayer-funded-anti-cannabis-ad-as-new-lawsuit-emerges">taxpayer-funded public service announcement</a> warning of impaired driving in states with legalized cannabis. At the same time, Trulieve <a href="https://www.benzinga.com/markets/cannabis/24/10/41156781/trulieve-sues-florida-gop-for-defamation-over-false-and-misleading-claims-as-cannabis-legalizati">filed a defamation lawsuit </a>against Florida's Republican Party, accusing it of misleading voters about the implications of Amendment 3.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41320395/florida-cannabis-legalization-gains-support-from-former-congressman-citing-economic-growth-publi">Florida Cannabis Legalization Gains Support From Former Congressman, Citing Economic Growth, Public Health</a></li>
</ul>
Photos: Eugenio Cuppone via Pixabay; Shutterstock

Cannabis

News

Legal

TCNNF

TSLA

Elon Musk-Linked Organization Donates $500,000 To Scuttle Florida Cannabis Legalization Amendment

Crude oil prices dropped sharply late Monday afternoon after The Washington Post reported Israeli Prime Minister Benjamin Netanyahu told the Biden administration he is willing to strike military targets rather than oil or <a href="https://www.benzinga.com/government/24/10/41298349/us-hits-iran-oil-exports-with-new-sanctions-after-israel-attack-crude-oil-holds-steady-at-75">nuclear facilities in Iran.&nbsp;</a>
The Details: Netanyahu told President Joe Biden in a call last Wednesday he is planning to target military infrastructure in a retaliatory strike against Iran, according to a U.S. official and an official <a href="https://www.washingtonpost.com/world/2024/10/14/israel-iran-strike-nuclear-oil-military/">familiar with the matter</a>. 
The sources also said Israel's action against Iran will be designed to avoid any perception of "political interference in the U.S. elections" noting an attack on Iranian oil facilities could send energy prices higher. The official familiar with the matter described Netanyahu as being in a "more moderated place" during the call between the two leaders.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41320277/oil-prices-drop-2-as-opec-cuts-forecast-irans-output-rises-analyst-says-netanyahu-m">Oil Prices Drop 2% As OPEC Cuts Forecast, Iran&#8217;s Output Rises: Analyst Says Netanyahu May Doubt US Commitment To &#8216;Restricting Iranian Exports&#8217;</a>
What Else: The United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) which tracks West Texas Intermediate (WTI) light crude fell 2.01% in Monday's regular trading session after OPEC lowered its 2024 global <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41320277/oil-prices-drop-2-as-opec-cuts-forecast-irans-output-rises-analyst-says-netanyahu-m">oil-demand growth forecast</a> and its 2025 global oil-demand growth forecast. 
In its Monthly Oil Market Report <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41320277/oil-prices-drop-2-as-opec-cuts-forecast-irans-output-rises-analyst-says-netanyahu-m">released on Monday</a>, OPEC reduced its 2024 oil demand growth estimate by 106,000 barrels per day (bpd), now expecting global demand to increase by 1.93 million bpd next year. Additionally, the forecast for 2025 demand growth was lowered by 102,000 bpd to 1.6 million bpd year-over-year.
The ProShares Ultra Bloomberg Crude Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCO#NYSE">UCO</a>) fund fell more than 2% in regular trading Monday following the lower global oil-demand growth forecast and is down another 4.51% at $27.50 after-hours. 
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a></li>
</ul>
Photo: Shutterstock

Commodities

Politics

Global

Movers

Oil Prices Drop After Netanyahu Says Israel Will Attack Military, Not Oil Or Nuclear Targets In Iran

Insured losses are way higher than originally anticipated due to the havoc from <a href="https://www.benzinga.com/markets/equities/24/10/41240852/back-to-back-hurricanes-batter-floridas-insurance-market-stocks-to-watch">back-to-back hurricanes</a>.
What Happened: Moody&#8217;s Risk Management Solutions, or RMS, <a href="https://www.rms.com/newsroom/announcement/2024-10-14/moodys-rms-event-response-us-private-market-insured-loss-estimate-for-hurricanes-helene-and-milton">crunched</a> the data to determine the financial impact of Hurricanes Milton and Helene. 
The firm expects total insured losses to range between $35 billion and $55 billion. 
That&#8217;s nearly quadruple what Moody's originally estimated, with losses falling between $8 billion and $14 billion. 
Hurricane Milton, the 13th named storm of the season, closely followed Hurricane Helene, which made landfall just two weeks earlier in Florida&#8217;s Big Bend region along the Gulf of Mexico.
Both storms hit many of the same areas, bringing widespread wind damage, storm surges, and inland flooding.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41317881/hurricane-milton-to-deliver-2-5b-blow-to-floridas-homebuilding-sector-goldman-sachs">Hurricane Milton To Deliver $2.5B Blow To Florida&#8217;s Homebuilding Sector, Goldman Sachs Says</a>
Why It Matters: Moody&#8217;s estimates help insurance companies, policymakers and other stakeholders assess the financial risks and prepare for the economic consequences of such events in the future.
And that&#8217;s important considering hurricane season typically runs until Nov. 30. 
But here&#8217;s the thing: Floridians already pay exorbitant homeowners&#8217; insurance premiums, <a href="https://www.orlandoweekly.com/news/experts-worry-floridas-2024-hurricane-season-could-wipeout-recent-homeowners-insurance-fixes-38005875">per</a> Orlando Weekly. With the immense damage caused by these storms, they&#8217;re going to be paying even more.
According to Moody&#8217;s Chief Risk Modeling Officer Mohsen Rahnama, several factors add uncertainty to the final loss estimates. These include the complexity of hazard patterns, such as the damaging tornadoes spawned by Milton's rainbands in southern Florida, and the storm's interaction with a mid-latitude jet, which created two swaths of the strongest winds. 
In some cases, structures already damaged by Helene may have sustained further damage from Milton. This complicates efforts to determine the primary cause of loss and leads to potential coverage issues.
It&#8217;s not just Helene and Milton. Overlapping insurance claims and Florida's annual deductibles may increase losses for properties previously damaged by past hurricanes, such as Ian in 2022.
Altogether, the Moody&#8217;s ground teams conducted &#8220;field reconnaissance&#8221; for more than 2,000 miles of damage.
&#8220;Our teams are still in Florida surveying the impacted areas,&#8221; Rahnama said.
Florida&#8217;s Insurance Problem: Several major insurance companies had already retreated from Florida due to the high risks associated with the state&#8217;s frequent hurricanes and rising litigation costs. The ones that remained include:
<ul>
<li>Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) </li>
<li>Travelers Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) </li>
<li>Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) </li>
<li>State Farm</li>
</ul>
Florida-only carriers will take the hardest hit, per a Moody&#8217;s report from Oct. 10. These insurance companies have at least 75% of their homeowners and commercial property premiums written in the state, the firm noted. 
&#8220;The top 10 Florida-only insurers write about 50% of the state&#8217;s homeowners business and are more vulnerable than others given their geographic concentration,&#8221; the company <a href="https://floridaphoenix.com/wp-content/uploads/2024/10/Moodys-Ratings_Hurricane-Milton_Reinsurers-10Oct2024-PBC_1425591-1.pdf">stated</a>. They include:
<ul>
<li>Citizens Property Insurance Corp.</li>
<li>Universal P&amp;C</li>
<li>Tower Hill</li>
<li>First Protective</li>
<li>Slide Insurance</li>
<li>Edison Insurance</li>
<li>Amer Integrity</li>
<li>Florida Peninsula</li>
<li>Homeowners Choice P&amp;C</li>
<li>Security First </li>
</ul>
ETFs To Watch: Three exchange-traded funds tracking public companies in the insurance space were all in the green at last check Monday:
<ul>
<li>SPDR S&amp;P Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIE#NYSE">KIE</a>), up 0.78%</li>
<li>iShares U.S. Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>), up 0.37%</li>
<li>Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>), up 0.58%</li>
</ul>
What&#8217;s Next: Moody's will provide a final industry loss estimate for Milton by the end of this week.
The National Hurricane Center is tracking a tropical depression in the Atlantic Ocean. 
Though it can bring heavy rain and cause flooding, a tropical depression is generally weak; if wind speeds increase beyond 39 miles per hour, it can develop into a tropical storm or hurricane if conditions allow.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Mon 10/14 8am EDT: <a href="https://twitter.com/hashtag/AL94?src=hash&amp;ref_src=twsrc%5Etfw">#AL94</a> has a chance of developing into a tropical depression as it approaches, or moves near the northern <a href="https://twitter.com/hashtag/LeewardIslands?src=hash&amp;ref_src=twsrc%5Etfw">#LeewardIslands</a> late this week. <a href="https://t.co/1aFZ3ykENk">pic.twitter.com/1aFZ3ykENk</a>
&mdash; National Hurricane Center (@NHC_Atlantic) <a href="https://twitter.com/NHC_Atlantic/status/1845796399990129124?ref_src=twsrc%5Etfw">October 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319060/s-p-500-extends-record-highs-dow-breaks-43-000-ahead-of-pivotal-earnings-week-bitco">S&amp;P 500 Extends Record Highs, Dow Breaks 43K, Bitcoin Rallies: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Photo: Shutterstock

Insurance

ETFs

iShares Dow Jones US Insurance Index Fund

KBWP

Hurricanes Helene, Milton Insurance Losses Spike To $55B: Moody's

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) showed off its humanoid robot, Optimus, at the company's "We, Robot&#8221; unveiling event last Thursday. According to a Bloomberg report, humans were remotely assisting the Optimus robot prototypes<a href="https://www.benzinga.com/news/24/10/41285210/tesla-stock-falls-nearly-3-in-overnight-trading-on-robinhood-after-self-driving-cybercab-unveil"> with some functions.</a>&nbsp;
The Details: Tesla CEO Elon Musk showcased the latest version of his Optimus robots during the Cybercab (robotaxi) reveal, which also happened at the event, and predicted the humanoid robots would become &#8220;the biggest product ever of any kind.&#8221; Musk did not reveal the robots were assisted or controlled remotely by humans. 
According to the Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-10-14/tesla-s-optimus-robots-were-remotely-operated-at-cybercab-event?srnd=homepage-americas&amp;sref=TBDibEcD">report</a>, Tesla employees remotely oversaw interactions between the Optimus robots and attendees of the event, said the sources who asked not to be identified. The sources reported the Optimus humanoid robot prototypes were able to walk unassisted using AI. Tesla did not immediately respond to Bloomberg's request for comment.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41295297/whats-going-on-with-sofi-technologies-stock">What&#8217;s Going On With SoFi Technologies Stock?</a>
Several videos posted on social media show event attendees interacting with the robots who served drinks, sang &#8220;Happy Birthday&#8221; and even danced with guests. A video <a href="https://x.com/minchoi/status/1845070881191612916">posted on X</a> shows an Optimus robot serving in a bartending role and confirming he was being remotely assisted by a human.&nbsp;
"Today, I'm assisted by a human. I'm not yet fully autonomous," the Optimus robot said in the video.&nbsp;
Another video <a href="https://x.com/Scobleizer/status/1844594008225611858">shows a guest</a> asking Optimus how much of the robot is controlled by AI.&nbsp;
&#8220;I can&#8217;t disclose just how much, that&#8217;s something you&#8217;ll have to find out later,&#8221; the robot said. &#8220;I would say, it might be some. I&#8217;m not going to confirm, but it might be some.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I asked. <a href="https://t.co/FkgPrdRlyW">pic.twitter.com/FkgPrdRlyW</a>
&mdash; Robert Scoble (@Scobleizer) <a href="https://twitter.com/Scobleizer/status/1844594008225611858?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Some Tesla influencers and investors said they felt betrayed or misled by Tesla's nondisclosure of Optimus' human assistance. But <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41298220/uber-analysts-unfazed-by-teslas-cybercab-reveal-eye-stronger-av-position">several analysts</a> felt Optimus' interactions with guests at the event were impressive and are a potential catalyst for the company.&nbsp;
Wedbush's Dan Ives <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41295072/tesla-robotaxi-day-event-more-fanfare-than-substance-8-analysts-on-cybercab-optimus">highlighted</a> "the massive improvements in Optimus&#8221; and said Cybercab and Optimus &#8220;could be a major financial contributor to Tesla&#8221; following last week's event.&nbsp;
TSLA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Tesla shares ended Monday's session 0.62% higher at $219.16.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Tech

Tesla's Optimus Robots Were Remotely Assisted By Humans At 'We, Robot' Event

These preliminary&nbsp;Third Quarter&nbsp;2024 revenue and Adjusted EBITDA results are within its previously announced&nbsp;guidance&nbsp;ranges.&nbsp;&nbsp;

Guidance

Forum Energy Technologies Reports Preliminary Q3 Revenue Of Approximately $208M (Est $214.5M), Bookings Of $205M

Federal Reserve Gov. Christopher J. Waller voiced concerns Monday over recent inflation data, signaling that the central bank must proceed cautiously <a href="https://www.benzinga.com/topic/interest-rates">on interest rate cuts. </a>
Speaking at a conference at Stanford University, Waller struck a slightly hawkish tone, highlighting the U.S. economy's strength while acknowledging worries over recent inflation upticks.
<h1 class="wp-block-heading">Solid Economic Growth but Disappointing Inflation</h1>
Waller emphasized the economy is on &#8220;solid footing,&#8221; with employment near the Federal Open Market Committee&#8217;s (FOMC) maximum objective. But he added, &#8220;The latest inflation data was disappointing.&#8221;
Despite progress in reducing inflation, recent figures suggest uneven progress toward the Fed&#8217;s 2% target.
Waller praised the economy&#8217;s resilience, noting that real GDP grew at a 2.2% annual rate in the first half of 2024 and is expected to accelerate in the third quarter. 
He also mentioned that household resources remain in good shape, though lower-income groups continue to face financial strain. &#8220;These revisions suggest that the economy is much stronger than previously thought, with little indication of a major slowdown in economic activity,&#8221; Waller said.
<h1 class="wp-block-heading">&#8216;Considerable Pent-Up Demand&#8217; As Interest Rates Fall</h1>
Waller highlighted continued strength in consumer spending, despite some moderation. 
Growth in personal consumption expenditures (PCE) has averaged around 2.5% this year. Waller&#8217;s business contacts expressed optimism about &#8220;considerable pent-up demand&#8221; for durable goods and home improvements, demand that has been delayed due to high interest rates.
As interest rates for credit cards and home equity loans begin to decline, Waller expects consumers to resume purchasing &#8220;durable goods, home improvements, and other big-ticket items.&#8221; 
&#8220;Now that rates have started to come down and are expected to come down more, consumers will be eager to make those purchases,&#8221; he said. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41314387/most-widely-hated-bull-market-reaches-2-year-milestone-top-20-s-p-500-stocks-drivin">&#8216;Most Widely Hated&#8217; Bull Market Reaches 2-Year Milestone: Top 20 S&amp;P 500 Stocks Driving The Rally</a>
<h1 class="wp-block-heading">Jobs Market Remains Quite Healthy</h1>
Waller also addressed the September jobs report, which far exceeded expectations. &#8220;The labor market remains quite healthy,&#8221; he said, pushing back against speculation that the Fed might have considered an emergency rate cut earlier in the summer. 
While Waller expects payroll gains to slow, he believes job growth will continue at a &#8220;solid rate.&#8221;
He did, however, caution that interpreting the October jobs report may be difficult due to temporary disruptions from recent hurricanes and the Boeing strike, which are expected to skew the numbers.
<h1 class="wp-block-heading">Inflation Rollercoaster and Rate Outlook</h1>
Turning to inflation, Waller expressed concern over September's likely increase in PCE inflation, the Fed's preferred measure. &#8220;We have made a lot of progress on inflation over the last year and a half, but that progress has clearly been uneven — at times it feels like being on a rollercoaster,&#8221; Waller said.
He remains uncertain whether the recent uptick in inflation is a temporary blip or a signal of more persistent inflationary pressures. &#8220;I will be watching the data carefully to see how persistent this recent uptick is,&#8221; he added.
Despite these concerns, Waller reaffirmed his outlook for gradual rate reductions over the next year, aligning with the FOMC&#8217;s median projection of 3.4% for the federal funds rate by the end of 2025. 
However, he acknowledged, &#8220;There is less certainty about the final destination.&#8221;
<h1 class="wp-block-heading">Market Reactions</h1>
Waller&#8217;s remarks have not significantly shifted interest-rate expectations. According to the CME FedWatch Tool, the odds of a 25-basis-point rate cut remained steady at 86%. 
However, if more Fed policymakers also express concerns about inflation in the days to come, and if Thursday's retail sales data exceeds expectations, the likelihood of the Fed holding rates unchanged could rise from here.
On Monday, Treasury yields were largely stable, with the two-year note yield — sensitive to rate policy — hovering around 4%. The U.S. dollar index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.3%, reaching its highest level since late July.
Meanwhile, the S&amp;P 500 index, monitored via the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gained 0.8% to close at 5,859 points, extending its record highs.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319060/s-p-500-extends-record-highs-dow-breaks-43-000-ahead-of-pivotal-earnings-week-bitco">S&amp;P 500 Extends Record Highs, Dow Breaks 43,000 Ahead Of Pivotal Earnings Week, Bitcoin&#8217;s Rally Lifts Crypto Stocks: What&#8217;s Driving Markets Monday?</a></li>
</ul>

Macro Economic Events

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

PowerShares DB US Dollar Index Bullish Fund

Fed's Waller Signals Caution On Interest-Rate Cuts: 'Latest Inflation Data Was Disappointing'

Offerings

Forum Energy Technologies Reports Commencement Of Backstopped Private Offering Of $100M Of 5-year Senior Secured Bonds

<a href="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/" title="https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/">https://www.forexlive.com/centralbank/feds-kashari-says-a-lot-of-progress-made-on-inflation-labor-market-is-strong-20241014/</a>

Fed's Kashkari Says We've Made A Lot Of Progress On Inflation, And Labor Market Is Strong; Not Worth It To Have Unemployment Rate Shoot Up; Don't Think China Is Remotely Competitive With U.S.; Not At All Worried That Yuan Could Replace Dollar As Global Reserve Currency; U.S. Competitive Position Is Very Very Strong, Though Can't Take It For Granted

INVO BioScience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares soared Monday after the company announced it closed <a href="https://www.benzinga.com/pressreleases/24/10/g41312767/invo-bioscience-and-naya-biosciences-close-merger-combined-company-to-operate-as-naya-biosciences-">its merger with NAYA Biosciences. </a>
The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The company expects to change its name to Naya Biosciences and trade on the Nasdaq under the &#8220;NAYA&#8221; ticker.&nbsp;
The combined company will be led by Invo CEO Steve Shum, Invo CFO Andrea Goren and Dr. Daniel Teper, founder and former CEO of Naya Biosciences, who will be appointed as president of the combined company and CEO of the Naya Therapeutics subsidiary.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41295297/whats-going-on-with-sofi-technologies-stock">What&#8217;s Going On With SoFi Technologies Stock?</a>
&#8220;We are confident that our expanded portfolio business model and combined assets have the potential to create significant value for both legacy and new shareholders,&#8221; said Steve Shum, CEO of the combined company.
&#8220;Combining scalable, profitable revenues from our fertility business with the upside of innovative therapeutics optimizes risk-return for investors. In addition, the hub-and-spoke model allows for shared resources and talent to accelerate the development of our lean, agile subsidiaries," Shum said.&nbsp;
Invo shares climbed on heavy trading volume following Monday's announcement with more than 54 million shares traded in the session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
INVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Invo BioScience shares are up 1.61% after-hours at $1.24 after gaining 92.55% in Monday&#8217;s regular session.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Health Care

Crowdsourcing

INVO

What Happened With Invo BioScience Stock Today?

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 15 years by 24.28% on an annualized basis producing an average annual return of 36.11%. Currently, Netflix has a market capitalization of $306.28 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 15 years ago, it would be worth $10,022.09 today based on a price of $713.67 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NFLX

Here's How Much $100 Invested In Netflix 15 Years Ago Would Be Worth Today

EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.7%. Currently, EOG Resources has a market capitalization of $74.42 billion. 
Buying $1000 In EOG: If an investor had bought $1000 of EOG stock 20 years ago, it would be worth $7,702.94 today based on a price of $130.89 for EOG at the time of writing.
<h3>EOG Resources's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728941421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $7,700 Today

ATEK

Athena Technology Acquisition Corp. II Says Financial Statements Contained Audit Opinion That Included Explanatory Paragraph Related To Ability To Continue As Going Concern

The text of the letter included:
Over much of the past two years, Medical Properties Trust has been the target of considerable scrutiny from short-selling hedge funds as well as certain media outlets.
In response to certain claims asserted by Viceroy Research, the Board&#39;s Audit Committee engaged Wachtell Lipton in early 2023 to conduct an independent investigation into the short-seller allegations, including with respect to MPT transactions involving Steward Healthcare beginning in 2016.
Wachtell Lipton in turn retained a leading global consulting firm to assist with financial forensics as part of this investigation. No limitations or restrictions were placed on the scope of the investigation and management cooperation with the investigation was exemplary.
The key findings from the investigation are as follows:
<ol>
<li>The investigation identified no evidence that MPT gratuitously overpays its operator-tenants for real estate.</li>
<li>The investigation identified no evidence of improper round-tripping.</li>
<li>The investigation found no evidence of improper recognition of &quot;uncollectable&quot; rent through GAAP-mandated straight-line revenue recognition. The investigation also found no evidence to substantiate the allegation that MPT was required to consolidate Steward&#39;s financial results.</li>
<li>The investigation concluded that neither Manolete Health nor MPT has an ownership interest in any Malta property or hospital.</li>
<li>The investigation yielded no evidence that management manipulated acquisitions or other metrics to meet compensation targets.</li>
<li>The investigation yielded no evidence of concerns regarding management integrity.</li>
</ol>

Medical Properties Trust Releases Letter To Shareholders Regarding Findings Of Independent, Forensic Investigation Into Short-seller Allegations; Says Board Continues To Stand Firmly Behind Its Management Team

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares popped in afternoon trading Monday after Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) announced intentions to purchase power from <a href="https://www.benzinga.com/topic/nuclear-energy">small modular reactor (SMR) developer Kairos Power</a>.
What Happened: Google on Monday said it would purchase power from a fleet of SMRs made by Kairos as the company and other tech giants increasingly turn to nuclear for energy needs related to the <a href="http://benzinga.com/topic/ai">AI</a> revolution, per <a href="https://www.cnbc.com/2024/10/14/google-inks-deal-with-nuclear-company-as-data-center-power-demand-surges.html">CNBC</a>.
&#8220;We believe that nuclear energy has a critical role to play in supporting our clean growth and helping to deliver on the progress of AI,&#8221; Michael Terrell, senior director for energy and climate at Google, reportedly told reporters. 
&#8220;The grid needs these kinds of clean, reliable sources of energy that can support the build-out of these technologies,&#8221; Terrell said. &#8220;We feel like nuclear can play an important role in helping to meet our demand, and helping meet our demand cleanly, in a way that's more around the clock.&#8221;
Big tech companies are increasingly looking to nuclear power to meet the rising energy demands of data centers. Data centers need to have reliable power at all times and nuclear offers an emissions-free option. Many hyperscalers also have emissions-reduction goals that they are trying to meet.
Google plans to have its first reactor online by 2030, with more reactors expected to follow through 2035. 
"It is an incredibly promising bet, and one that, you know, if we can get these projects to scale and then scale globally, will deliver enormous benefits to communities and power grids around the world," Terrell said.
See Also: <a href="https://www.benzinga.com/news/24/10/41309060/nvidias-jensen-huang-says-chatgpt-led-to-awakening-of-ai-praises-sam-altmans-openai-as-one-of-most-c">Nvidia&#8217;s Jensen Huang Says ChatGPT Led To &#8216;Awakening Of AI,&#8217; Praises Sam Altman&#8217;s OpenAI As One Of Most Consequential Companies Of Our Time</a>
The Google news helped lift nuclear stocks across the board on Monday, but Oklo was among the biggest gainers. Investors may be speculating that Oklo could be one of the next companies to ink a deal with a big tech player, given the company&#8217;s ties to OpenAI and Sam Altman. 
Oklo went public in May through a merger with <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37906984/sam-altmans-under-the-radar-spac-fuses-ai-expertise-with-nuclear-energy-here-are-the-oth">AltC Acquisition Corp</a>, a special purpose acquisition company (SPAC) backed by Altman, who has also been the chair of Oklo&#8217;s board since 2015. Oklo is the only public company that Altman chairs.
Given Altman&#8217;s involvement with Oklo and OpenAI&#8217;s leadership in the AI space, it wouldn&#8217;t be surprising to see the companies work together in some capacity to meet rising energy demand. 
OpenAI&nbsp;recently <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">secured new funding</a> at a valuation of $157 billion&nbsp;from investors including Nvidia, Microsoft, Thrive Capital, SoftBank and Ark Funds.
OKLO Price Action:&nbsp;<a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a>&nbsp;closed Monday up at 9.73%. The stock was up another 3.78% in after-hours, trading at $10.42, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Oklo.

After-Hours Center

GOOG

GOOGL

OKLO

Sam Altman's Oklo Jumps On Google Nuclear Deal: What's Going On?

Arm Holdings PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) has seen gains over the past week. Here&#8217;s <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41185402/arm-stock-softbanks-ai-goals-vs-bearish-market-trends">what you need to know.</a>
What To Know: The demand for semiconductors has grown, driven by advancements in artificial intelligence and mobile technology. Arm's technology is a critical component in devices such as smartphones and cloud services. Additionally, the partnership with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) for the iPhone 16 may have also influenced investor confidence in the company.
Financially, Arm reported record revenue of $939 million for Fiscal year 2025, representing a 39% increase from the previous year. The gross margin stands at 96.5%, with licensing revenue growing by 72%. Currently, Arm is trading within a 52-week range of $46.50 to $188.75. The session volume reached 8.942 million shares, exceeding the 100-day average volume of 7.928 million shares.
The stock is also trending on social media such as Yahoo Finance and StockTwits, attracting increased investor attention and engagement.
ARM Price Action: Arm Holdings shares were up by 6.84% at $162.82 at market close Monday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png" alt="" class="wp-image-594802" style="width:494px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14165055/ARM.png 1456w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41320620/unitedhealth-group-q3-earnings-preview-dow-jones-industrial-average-stock-could-move-marke">UnitedHealth Group Q3 Earnings Preview: Dow Jones Industrial Average Stock Could &#8216;Move Markets&#8217; Tuesday</a></li>
</ul>
Photo: Shutterstock.

AAPL

Arm Holdings Stock Climbs In A Week As Semiconductor Sector Strengthens

– Engineering Union Spokesperson

Management

Boeing To Send 60-Day Notices In Mid November To Staff Being Made Redundant As Part Of Sweeping Job Cuts

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- &nbsp;
-- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle --
NEWTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) posted final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Mouthpiece (HCPCS code A4594) at $2,963.30 to be implemented January 1, 2025 and deferred final national determination of the payment rate for the PoNS Controller (HCPCS Code A4593) to the next payment cycle.

HSDT

Helius Medical Technologies Announces Reimbursement Determination For PoNs Mouthpiece Set At $2,963.30 On Lump Sum Payment To Be Challenged By Co; Disagrees With CMS' Methods, Pricing & Deferral For Determining Payment Rates For PoNs Mouthpiece & Pons Controller

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $128.22, a high estimate of $143.00, and a low estimate of $120.00. Marking an increase of 4.61%, the current average surpasses the previous average price target of $122.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939648_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Abbott Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Abbott Laboratories showcased positive performance, achieving a revenue growth rate of 4.0% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Abbott Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Abbott Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock

In the last three months, 5 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1728939642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Betterware de Mexico SAPI. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Betterware de Mexico SAPI's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Betterware de Mexico SAPI's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Betterware de Mexico SAPI</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>Betterware de Mexico SAPI's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Betterware de Mexico SAPI showcased positive performance, achieving a revenue growth rate of 5.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 19.61%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.75%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 3.46, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Assessing Betterware de Mexico SAPI: Insights From 5 Financial Analysts

Hancock Whitney Corporation (HWC) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hancock Whitney (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwc-stock-quote/">HWC</a>) just reported results for the second quarter of 2024.<ul><li>Hancock Whitney reported earnings per share of $1.31. This was above the analyst estimate for EPS of $1.20.</li><li>The company reported revenue of $359.60 million.</li><li>This was 0.13% better than the analyst estimate for revenue of $359.12 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/07/hwc-stock-earnings-hancock-whitney-for-q2-of-2024/">HWC Stock Earnings: Hancock Whitney Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HWC Stock Earnings: Hancock Whitney Beats EPS, Beats Revenue for Q2 2024

In a report released yesterday, Catherine Mealor from KBW maintained a Buy rating on Hancock Whitney (HWC – Research Report), with a price target o...

KBW Keeps Their Buy Rating on Hancock Whitney (HWC)

In a report released today, Stephen Scouten from Piper Sandler assigned a Buy rating to Hancock Whitney (HWC – Research Report), with a price targe...

Hancock Whitney (HWC) Receives a Buy from Piper Sandler

Truist Financial analyst Brandon King maintained a Hold rating on Hancock Whitney (HWC – Research Report) today and set a price target of $57.00. T...

Truist Financial Keeps Their Hold Rating on Hancock Whitney (HWC)

Hancock Whitney: Still Room For Upside After A Solid Q2

Hancock Whitney declares $0.40 dividend

Stocks with three weeks of deteriorating technicals by Piper Sandler

In a report released yesterday, Brandon King from Truist Financial maintained a Hold rating on Hancock Whitney (HWC – Research Report), with a pric...

Comments

Hancock Whitney

Notizie

Ultime notizie per Hancock Whitney (NASDAQ:HWC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO